5:30 PM
 | 
Feb 15, 2013
 |  BC Extra  |  Company News

ViiV's dolutegravir gets Priority Review

FDA accepted and granted Priority Review to an NDA from ViiV Healthcare Ltd. for dolutegravir to treat HIV infection in patients ages 12 and over. The PDUFA date is Aug. 17....

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >